The Arab Drug Company produces and sells pharmaceutical products.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م57.07|
|52 Week High||ج.م54.21|
|52 Week Low||ج.م82.22|
|1 Month Change||-5.72%|
|3 Month Change||-11.27%|
|1 Year Change||-9.70%|
|3 Year Change||104.99%|
|5 Year Change||749.26%|
|Change since IPO||358.60%|
Recent News & Updates
|ADCI||EG Pharmaceuticals||EG Market|
Return vs Industry: ADCI underperformed the EG Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: ADCI underperformed the EG Market which returned 8.2% over the past year.
Stable Share Price: ADCI is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: ADCI's weekly volatility (2%) has been stable over the past year.
About the Company
|1963||1,148||R. Samah Abdel-Yassiz||https://www.adcopharma.com|
The Arab Drug Company produces and sells pharmaceutical products. It offers ampoules, tablets, syrups, solutions, capsules, aerosol sprays, metered dose inhalers, granulated powder for suspension, creams, ointments, and suppositories. The company was incorporated in 1963 and is based in Cairo, Egypt.
Arab Drug Fundamentals Summary
|ADCI fundamental statistics|
Is ADCI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADCI income statement (TTM)|
|Cost of Revenue||ج.م306.75m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||17.01|
|Net Profit Margin||19.00%|
How did ADCI perform over the long term?See historical performance and comparison
4.4%Current Dividend Yield
Is Arab Drug undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ADCI (EGP57.07) is trading above our estimate of fair value (EGP46.75)
Significantly Below Fair Value: ADCI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ADCI is good value based on its PE Ratio (3.4x) compared to the EG Pharmaceuticals industry average (5.5x).
PE vs Market: ADCI is good value based on its PE Ratio (3.4x) compared to the EG market (12.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADCI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADCI is good value based on its PB Ratio (1.1x) compared to the EG Pharmaceuticals industry average (1.3x).
How is Arab Drug forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arab Drug has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Arab Drug performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADCI has a high level of non-cash earnings.
Growing Profit Margin: ADCI's current net profit margins (19%) are higher than last year (17.8%).
Past Earnings Growth Analysis
Earnings Trend: ADCI's earnings have grown significantly by 33.6% per year over the past 5 years.
Accelerating Growth: ADCI's earnings growth over the past year (10%) is below its 5-year average (33.6% per year).
Earnings vs Industry: ADCI earnings growth over the past year (10%) underperformed the Pharmaceuticals industry 10%.
Return on Equity
High ROE: ADCI's Return on Equity (33%) is considered high.
How is Arab Drug's financial position?
Financial Position Analysis
Short Term Liabilities: ADCI's short term assets (EGP375.1M) exceed its short term liabilities (EGP136.6M).
Long Term Liabilities: ADCI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ADCI's debt to equity ratio (6.8%) is considered satisfactory.
Reducing Debt: ADCI's debt to equity ratio has reduced from 19.5% to 6.8% over the past 5 years.
Debt Coverage: ADCI's debt is well covered by operating cash flow (172.5%).
Interest Coverage: ADCI earns more interest than it pays, so coverage of interest payments is not a concern.
What is Arab Drug current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ADCI's dividend (4.38%) is higher than the bottom 25% of dividend payers in the EG market (2.69%).
High Dividend: ADCI's dividend (4.38%) is low compared to the top 25% of dividend payers in the EG market (7.43%).
Stability and Growth of Payments
Stable Dividend: ADCI has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: ADCI's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (18.2%), ADCI's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
R. Samah Abdel-Yassiz
Dr. R. Samah Mustafa Abdel-Yassiz serves as the Chairman of the Board and Managing Director at The Arab Drug Company.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
The Arab Drug Company's employee growth, exchange listings and data sources
- Name: The Arab Drug Company
- Ticker: ADCI
- Exchange: CASE
- Founded: 1963
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م342.420m
- Shares outstanding: 6.00m
- Website: https://www.adcopharma.com
Number of Employees
- The Arab Drug Company
- 5 EL Massanei Street
- AL Amireya
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 16:16|
|End of Day Share Price||2021/10/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.